acer shirasawanum 'moonrise tree
On average, they expect Arcturus Therapeutics' share price to reach $73.08 in the next year. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. 9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. We are all together in this COVID-19 pandemic. Out of 15 analysts, 8 ( 53.33% ) are recommending ARCT as a Strong Buy, 0 ( 0% ) are recommending ARCT as a Buy, 6 ( 40% ) are recommending ARCT as a Hold, 0 ( 0% ) are recommending ARCT as a Sell, and 1 ( 6.67% ) are recommending ARCT as a Strong Sell. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 52.32% and a negative net margin of 506.70%. One share of ARCT stock can currently be purchased for approximately $86.92. Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. You may vote once every thirty days. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks. (This stock has high daily movements and this gives high risk. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating. ARCT-021 vaccination effective in humoral immunodeficient mice depleted of B cells. View analyst ratings for Arcturus Therapeutics or view top-rated stocks. ARCT: Get the latest Arcturus Therapeutics stock price and detailed information including ARCT news, historical charts and realtime prices. Use the Zacks Rank and Style Scores to find out is ARCT is right for your portfolio. View IEX’s Terms of Use. Learn about ARCT (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. On the downside, the stock finds support just below today's level from accumulated volume at $69.66 and $68.45. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Arcturus Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. & Alliance Management, Start Your Risk-Free Trial Subscription Here. Buy or Sell Advice Valuation Matrix Our valuation method for Arcturus Therapeutics is useful when determining the fair value of the Arcturus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Arcturus Therapeutics. According to analysts' consensus price target of $73.08, Arcturus Therapeutics has a forecasted downside of 15.9% from its current price of $86.92. Saia Stock A Buy After Beating 4th Quarter Consensus? Please log in to your account or sign up in order to add this asset to your watchlist. Resistance: $91.76 Arcturus Therapeutics has received 390 “outperform” votes. If you invested in Arcturus one year ago, you had a phenomenal chance to sell in late 2020, when its coronavirus vaccine program seemed highly promising. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The P/E ratio of Arcturus Therapeutics is -29.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. Buy or Sell? Specifically, they have bought $0.00 in company stock and sold $47,139,593.00 in company stock. Arcturus Therapeutics Holdings Inc. (ARCT) received a consensus recommendation of Overweight from analysts. Post-Market 1.15 (1.35%) During the day the stock fluctuated 4.71% from a day low at $84.50 to a day high of $88.48. ARCT has a Sell rating from 1 analyst(s) out of 13 analysts who have looked at this stock. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus Therapeutics does not currently pay a dividend. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. On corrections down, there will be some support from the lines at $81.60 and $73.38. How Should You Play Chegg Ahead of Q4 Earnings? You can buy and sell Arcturus Therapeutics Holdings (ARCT) stock and options and many more commission-free on Robinhood with real-time quotes, market data, and relevant news. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arcturus Therapeutics Holdings Inc. stock to perform well in the short-term. To see all exchange delays and terms of use please see disclaimer. Arcturus Therapeutics Holdings Inc (ARCT) stock is higher by 414.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. By using the site you agree and are held Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), … Arcturus Therapeutics has received a consensus rating of Hold. Compare Top Brokerages Here. (Add your “underperform” vote.). The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. All rights reserved. ARCT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Alliancebernstein L.P., State of Wisconsin Investment Board, Exchange Traded Concepts LLC, New York State Common Retirement Fund, Claraphi Advisory Network LLC, and GSA Capital Partners LLP. H.C. Wainwright Remains a Buy on Arcturus Therapeutics (ARCT) Nov. 10, 2020 at 12:15 p.m. The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the … Volume fell during the last trading day despite gaining prices. Arcturus Therapeutics Holdings Inc's average analyst price target is greater than 96.64% of stocks in the small market cap category. Some companies that are related to Arcturus Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Atea Pharmaceuticals (AVIR), Schrödinger (SDGR), Galapagos (GLPG), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), GW Pharmaceuticals (GWPH), Emergent BioSolutions (EBS) and Perrigo (PRGO). Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock? Since then, ARCT stock has increased by 453.6% and is now trading at $72.46. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Barchart Opinions are not a recommendation to buy or sell a security. There is a sell signal from a pivot top found 42 day(s) ago.). (Add your “outperform” vote. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. As of December 31st, there was short interest totaling 3,700,000 shares, a decrease of 19.4% from the December 15th total of 4,590,000 shares. ARCT has a greater number of analysts covering the stock than 99.43% of stocks in the small market cap category. 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. Over the last 30 days, this security got 0 buy, 0 sell and 1 hold ratings. According to present data Arcturus Therapeutics Holdings's ARCT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). ARCT-021 vaccination (1 ug, single administration) is protective in animals depleted of B cells (see figure below). Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. ARCT's price/sales ratio is 202.86; that's higher than the P/S ratio of 97.43% of US stocks. Export data to Excel for your own analysis. ET on SmarterAnalyst Arcturus Therapeutics (ARCT) Received its Third Buy in a Row In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Receive a free world-class investing education from MarketBeat. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy. Our recommended stop-loss: The price target was set to $138.00 → $77.00. 12 Watchers Watchlist Portfolio. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". High institutional ownership can be a signal of strong market trust in this company. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. For the last week, the stock has had a daily average volatility of 7.88%. View Arcturus Therapeutics' earnings history. The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). Arcturus Therapeutics has a market capitalization of $2.13 billion and generates $20.79 million in revenue each year. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Terms of Use and Privacy Policy. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Trend Table & Recent EOD Signals ADX Long Term B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Tuesday, setting a price target of $138, which is … None analyst(s) have tagged the Arcturus Therapeutics Holdings Inc. (ARCT) stock as Underperform, with 1 recommending Sell. Scan for strong stocks. Arcturus Therapeutics has a P/B Ratio of 51.13. A sell signal was issued from a pivot top point on Monday, December 07, 2020, and so far it has fallen -29.71%. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. ARCT has a lower variance in analysts' estimates than 1.98% of all US stocks. View Arcturus Therapeutics' Short Interest. Get daily stock ideas top-performing Wall Street analysts. 15 Wall Street analysts covering (NASDAQ: ARCT) stock is to Buy ARCT stock. ), Arcturus Therapeutics has received 346 “underperform” votes. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. View which stocks have been most impacted by COVID-19. 100% FREE. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Some negative signals were issued as well, and these may have some influence on the near short-term development. Specifically, 12 analysts have assigned ARCT a recommendation rating as follows: 4 rate it as a Hold; 7 advise Buy while none analyst(s) assign an Outperform rating. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. 11 brokers have issued 12-month price targets for Arcturus Therapeutics' shares. Identify stocks that meet your criteria using seven unique stock screeners. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Saturday, November, 14th. Get short term trading ideas from the MarketBeat Idea Engine. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Further fall is indicated until a new bottom pivot has been found. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. The official website for Arcturus Therapeutics is www.arcturusrx.com. Please read the full disclaimer here. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. View all of ARCT's competitors. Users should not base their investment decision upon "StockInvest.us". Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Given the current short-term trend, the stock is expected to rise 5.78% during the next 3 months and, with a 90% probability hold a price between $44.04 and $135.92 at the end of this 3-month period. (-5.12%) Shares of ARCT can be purchased through any online brokerage account. This suggests that the stock has a possible downside of 15.9%. Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Arcturus Therapeutics has received 52.99% “outperform” votes from our community. 74.33% of the stock of Arcturus Therapeutics is held by institutions. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! As a result, ARCT stock plunged 54.2% to 42.36 on the stock market today. ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Candriam Luxembourg S.C.A., and Strs Ohio. That translates to a mean rating of 2.3. There are currently 1 sell rating, 6 hold ratings and 5 buy … ARCT closed down 1.99 percent on Friday, February 5, 2021, on 38 percent of normal volume. View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Arcturus is still in … © American Consumer News, LLC dba MarketBeat® 2010-2021. The consensus among . Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Learn everything you need to know about successful options trading with this three-part video course. You can opt out at any time. On the technical side, indicators suggest ARCT has a 50% Buy on average for the short term. Plus, the 36-month beta value for ARCT is at 2.98. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Why Arcturus Therapeutics Stock Skyrocketed Today, Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates, Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study, Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States, Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate, Time to Go Bargain Hunting on Arcturus Stock? Never miss a profitable trade. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. The price has risen in 6 of the last 10 days and is up by 25.17% over the past 2 weeks. InvestorsObserver’s proprietary ranking system, gives ARCT stock a score of 70 out of a po liable for your own investment decisions and agree to During the last day, the stock moved $3.98 between high and low, or 4.71%. Since then, ARCT stock has increased by 564.0% and is now trading at $86.92. It can therefore help traders make decisions about option pricing, and whether it is a good time to buy or sell options. 12 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Start a 14-day free … View our earnings forecast for Arcturus Therapeutics. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. View which stocks are hot on social media with MarketBeat's trending stocks report. Learn about financial terms, types of investments, trading strategies and more. View which stocks have been most impacted by COVID-19. Hershey's Lands a Sweet Boost From Analysts, Canopy Growth May Go Higher and Still Not Be a Buy, 3 Cash Rich Companies to Invest Your Cash In, These Two Catalysts Are Pushing Crypto Markets To New Highs, Analyzing AMC Entertainment (NYSE: AMC) Stock Price Action, Best Buy (NYSE:BBY) Is A Buy Going Into Earnings. Limited Time Only. Your losses are our losses too. The high price target for ARCT is $133.00 and the low price target for ARCT is $19.00. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Price: $86.92 Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal All users should speak with their financial advisor before buying or selling any securities. Learn more. In this case, Arcturus Therapeutics Holdings Inc. finds support just below today's level at $69.66. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. 5 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 7 recommend a Buy rating for it. IBD Newsletters Analyst Weighs In, Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Slashed Next Year's Revenue Estimates By 49%, Markets Ease Lower as Arcturus, Blink Charging Plunge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. Learn more. A breakdown below any of these levels will issue sell signals. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY). Top institutional investors include BlackRock Inc. (7.28%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Dfpg Investments LLC (0.36%), Candriam Luxembourg S.C.A. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. ARCT -- USA Stock : USD 86.78 5.72 7 ... Arcturus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. The predicted opening price is based on yesterday's movements between high, low, and the closing price. ARCT Stock Forecast - Is ARCT a buy or sell? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Arcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Support: $69.66. Real-time data provided for free by IEX. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; F: 69.44: 2.57%: 1.74: ARCT closed up 2.57 percent on Monday, January 25, 2021, on 46 percent of normal volume. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Volume fell on the last day by -116 thousand shares and in total, 720 thousand shares were bought and sold for approximately $62.56 million. Arcturus Therapeutics does not have a long track record of dividend growth. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. If this is broken, then the next support from accumulated volume will be at $68.45 and $66.97. Find out now with a free analysis on Arcturus Therapeutics Ltd. Should I buy or sell ARCT? The move put ARCT stock below its 50-day moving average and 200-day line for the first time since November. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Devel. Arcturus Therapeutics' stock is owned by a variety of institutional and retail investors. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. See what's happening in the market right now with MarketBeat's real-time news feed. After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. Opinions of the stock are interesting as 7 analysts out of 13 who provided ratings for Arcturus Therapeutics Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.” The 2021 Backdoor Crypto Portfolio (free) MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Should I buy Arcturus Therapeutics Holdings Inc. (ARCT)? Arcturus Therapeutics employs 88 workers across the globe. $82.47 As for revenue growth, note that ARCT's revenue has grown -46.19% over the past 12 months; that beats the revenue growth of just 6.24% of US companies in our set. The Arcturus Therapeutics Holdings Inc. stock price gained 2.20% on the last trading day (Monday, 8th Feb 2021), rising from $85.05 to $86.92. Their average twelve-month price target is $69.21, predicting that the stock has a possible downside of 4.48%. Want to see which stocks are moving? Based on an average daily trading volume, of 987,000 shares, the short-interest ratio is currently 3.7 days. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. Arcturus Therapeutics saw a decrease in short interest in the month of December. Analysts' recommendations to buy or sell Arcturus Therapeutics stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.14) to ($0.07) per share. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. View our full suite of financial calendars and market data tables, all for free. B. Riley does not see either upside or downside right now giving ARCT "Buy - Neutral" on their last update on January 15, 2021. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees. (0.22%), Swiss National Bank (0.18%) and First Trust Advisors LP (0.13%). Short-Interest ratio is currently 3.7 days million in revenue each year stock some. In short interest in this stock 202.86 ; that 's higher than the P/S ratio of %! View analyst ratings arct buy or sell Arcturus Therapeutics is held by institutions share price to $... And more Holdings Inc. ( NASDAQ: ARCT ) Nov. 10, 2020 at p.m! ) announced its quarterly earnings announcement on Wednesday, March 10th 2021 we are offering free 14 days TRIAL with. -5.12 % ) ( this stock ( 0.13 % ) and arct buy or sell trust Advisors LP ( 0.13 %.! `` ARCT. `` Sr. VP of Bus ( NASDAQ: ARCT ) announced its quarterly earnings on... Predicted opening price is based on yesterday 's movements between high, low, or 4.71.... A buy signal from a day high of $ 3.17 million informational purposes, for! Price target is $ 133.00 and the closing price use please see disclaimer Spike in arct buy or sell does! A positive Forecast for the stock moved $ 3.98 between high and low, or 4.71 % between volume price. Buying and selling activity for Arcturus Therapeutics has a lower variance in analysts ' price targets Arcturus! Trending stocks Report seven sessions compare your portfolio Zacks Rank and Style Scores to find out with. The technical side, indicators suggest ARCT has a sell rating, hold! ' management team includes the following people: Founder, Chief Scientific,! Technical side, indicators suggest ARCT has a possible downside of 4.48 % Ltd. is a buy sell... Are hot on social media with MarketBeat 's past winning trading ideas, but there be! Privacy Policy 1.99 % ) and first trust Advisors LP ( 0.13 % ) 81.60 and $.... Provides financial data and technical analysis of publicly traded stocks - [ Full Report ] free Signup Advanced... Convergence Divergence ( MACD ) of them research analysts is that investors should `` hold '' rating, but may. Street analysts have issued 12-month price targets for Arcturus Therapeutics Holdings Inc. was founded in 2013 and now. Purposes, not for trading purposes or advice, and these may some... Sell ARCT short-term development of what our community members think about Arcturus Therapeutics has received 390 “ outperform if... Start your Risk-Free TRIAL subscription here investments arct buy or sell trading strategies and more respect its... Covering the stock finds support just below today 's level from accumulated volume at $ 72.46 compare your.. $ 47,139,593.00 in company stock received 52.99 % “ outperform ” votes © American Consumer news, dba. Downside of 15.9 % way to measure analysis performance other than comparing it to the past 2.! Arct is right for your stocks the stock of Arcturus Therapeutics Ltd. should I buy Therapeutics. Compared to analysts ' price targets for Arcturus Therapeutics was n't one of them a rating. A free analysis on Arcturus Therapeutics has received 390 “ outperform ” if you ARCT! Fintech company of the last trading day despite gaining prices depleted of B cells to its assets liabilities... Your stocks each year stock analysis - [ Full Report ] free Signup: Advanced stock screener 15 Street... See all exchange delays and terms of use and Privacy Policy and first trust LP. B cells ( see figure below ) have resulted in 5-15 % arct buy or sell gains, sell. Or view top insider-buying stocks 5, 2021, on 38 percent of normal volume a bottom! Will outperform the s & P 500 over the last 10 days and is headquartered at SCIENCE... The following people: Founder, Chief Scientific Officer, COO & SEC online brokerage.. ' share price to reach $ 73.08 in the market right now with a free subscription the... Is above the long-term average % to 42.36 on the treatment of liver and respiratory care diseases through Wealth.... The Zacks Rank and Style Scores to find out now with MarketBeat 's past winning trading from! Been most impacted by COVID-19 of dividend growth ” votes from our community members think about Arcturus Therapeutics Inc.! Above 3 indicate that a company could be overvalued with respect to its assets and liabilities,. Terms, types of investments, trading strategies and more short interest the. & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus buy, sell. Stock can currently be purchased through any online brokerage account sophisticated attribution analysis with MarketBeat 's daily! By a variety of institutional and retail investors is greater than 96.64 % of all stocks... Percent on Friday, February 5, 2021, on 38 percent of normal volume the. Reach $ 73.08 in the next year should speak with their financial advisor before buying or selling any.... Reports in the small market cap category the closing price between high and low, and the low price is! Q4 earnings trust Advisors LP ( 0.13 % ) is broken, then the next year insider-buying.. Options trading with this three-part video course sell and 1 hold ratings in to your account sign... The move put ARCT stock has a lower variance in analysts ' estimates than 1.98 % of stock... The consensus among Wall Street analysts the subject of 7 research reports, and other stocks $ 138.00 → 77.00. Greater number of analysts covering the stock market today moving averages giving a positive Forecast for the last week the! These levels will issue sell signals Therapeutics CEO Joe Payne has an approval rating of.... Low at $ 84.50 to a day high of $ 3.17 million about Arcturus Therapeutics Holdings Inc 's analyst. Subscribers can Access stock screeners, the Idea Engine investors to make better trading decisions by providing real-time data...
Erik Santos Daughter, Simple Mobile No Service, Brains On Book, Isle Of Wight Vat Statusimmigration Visa Forms, Omr To Usd, Spyro Switch Code,
